Skip to main navigation Skip to search Skip to main content

SGLT-2 Inhibitors in NAFLD: Expanding Their Role beyond Diabetes and Cardioprotection?

  • Theodoros Androutsakos
  • , Narjes Nasiri-Ansari
  • , Athanasios-Dimitrios Bakasis
  • , Ioannis Kyrou
  • , Efstathios Efstathopoulos
  • , Harpal S. Randeva*
  • , Eva Kassi*
  • *Corresponding author for this work
    • Department of Pathophysiology, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece
    • Unit of Molecular Endocrinology, Department of Biological Chemistry, Medical School, National and Kapodistrian University of Athens,11527 Athens, Greece
    • 2nd Department of Radiology, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece
    • Warwickshire Institute for the Study of Diabetes, Endocrinology and Metabolism (WISDEM), University Hospitals Coventry and Warwickshire NHS Trust, Coventry, CV2 2DX, United Kingdom; Warwick Medical School, University of Warwick, Coventry, CV4 7AL, United Kingdom
    • Unit of Molecular Endocrinology, Department of Biological Chemistry, Medical School, National and Kapodistrian University of Athens,11527 Athens, Greece; Endocrine Oncology Unit, 1st Department of Propaedeutic Internal Medicine, Laiko Hospital, National and Kapodistrian University of Athens, 11527 Athens, Greece

    Research output: Contribution to journal › Review article › peer-review

    20 Downloads (Pure)

    Abstract

    Non-alcoholic fatty liver disease (NAFLD) is an ‘umbrella’ term, comprising a spectrum ranging from benign, liver steatosis to non-alcoholic steatohepatitis, liver fibrosis and eventually cirrhosis and hepatocellular carcinoma. NAFLD has evolved as a major health problem in recent years. Discovering ways to prevent or delay the progression of NAFLD has become a global focus. Lifestyle modifications remain the cornerstone of NAFLD treatment, even though various pharmaceutical interventions are currently under clinical trial. Among them, sodium-glucose co-transporter type-2 inhibitors (SGLT-2i) are emerging as promising agents. Processes regulated by SGLT-2i, such as endoplasmic reticulum (ER) and oxidative stress, low-grade inflammation, autophagy and apoptosis are all implicated in NAFLD pathogenesis. In this review, we summarize the current understanding of the NAFLD pathophysiology, and specifically focus on the potential impact of SGLT-2i in NAFLD development and progression, providing current evidence from in vitro, animal and human studies. Given this evidence, further mechanistic studies would advance our understanding of the exact mechanisms underlying the pathogenesis of NAFLD and the potential beneficial actions of SGLT-2i in the context of NAFLD treatment.
    Original languageEnglish
    Article number3107
    JournalInternational Journal of Molecular Sciences
    Volume23
    Issue number6
    DOIs
    Publication statusPublished - 13 Mar 2022

    Bibliographical note

    © 2022 by the authors.
    Licensee MDPI, Basel, Switzerland.
    This article is an open access article
    distributed under the terms and
    conditions of the Creative Commons
    Attribution (CC BY) license
    (https://creativecommons.org/license
    s/by/4.0/).

    UN SDGs

    This output contributes to the following UN Sustainable Development Goals (SDGs)

    1. SDG 3 - Good Health and Well-being
      SDG 3 Good Health and Well-being

    Keywords

    • MAFLD
    • Metabolic syndrome
    • NAFLD
    • Non-alcoholic fatty liver disease
    • SGLT-2
    • Sodium-glucose co-transporter type-2 inhibitors

    Fingerprint

    Dive into the research topics of 'SGLT-2 Inhibitors in NAFLD: Expanding Their Role beyond Diabetes and Cardioprotection?'. Together they form a unique fingerprint.

    Cite this